Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean company engaged in the research and development of platform technology-based immuno-oncology drugs and related IT businesses. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, EU101, and Antibody.
Contact
58 Gasan Digital 1-ro
4th Floor, Room 408, Ace Hansol Tower
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
120
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,940.10 | 34.10 | -0.38% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 24,842.72 | 368.09 | -1.46% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 64,474.99 | 1,947.61 | -2.93% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,769.10 | 26.60 | -0.30% |
| SSE Composite Index | 3,822.38 | 54.40 | -1.40% |